Skip to main content
SpringerLink
Log in
Book cover

Biologic and Systemic Agents in Dermatology pp 159–174Cite as

Nail, Scalp, and Palmoplantar Psoriasis

  • Chapter
  • First Online:

Abstract

Psoriasis can affect many areas of the body and treatments should target the areas of involvement. Nail disease is difficult to treat with topical therapy as the vehicle must be optimized to penetrate the nail and surrounding tissues. Some of the inflammation in nail disease is deep in the nail matrix and thus difficult for topical therapies to access. Scalp disease is difficult to treat with topical and phototherapy due to the presence of hair, bathing habits, and convenience issues. The palms and soles often have particularly thick plaques of psoriasis which may prevent absorption of topical therapy and resist phototherapy. Patients with primarily palmoplantar disease often do not respond to multiple therapies, and many require combination therapy for disease control. Collectively, nail, scalp, and palmoplantar psoriasis are considered “tough to treat” and often do not respond as well as plaque psoriasis elsewhere on the body. This chapter critically addresses the challenges posed by each condition and evaluates available treatment options.

This is a preview of subscription content, log in via an institution.

References

  1. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27.

    Article  PubMed  Google Scholar 

  2. de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193(4):300–3.

    Article  PubMed  Google Scholar 

  3. van der Velden HM, Klaassen KM, van de Kerkhof PC, Pasch MC. The impact of fingernail psoriasis on patients’ health-related and disease-specific quality of life. Dermatology. 2014;229(2):76–82.

    Article  PubMed  Google Scholar 

  4. Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–8.

    Article  CAS  PubMed  Google Scholar 

  5. Armesto S, Esteve A, Coto-Segura P, Drake M, Galache C, Martinez-Borra J, et al. Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients. Actas Dermosifiliogr. 2011;102(5):365–72.

    Article  CAS  PubMed  Google Scholar 

  6. Chandran V, Schentag CT, Gladman DD. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol. 2008;35(10):2069–70; author reply 70.

    PubMed  Google Scholar 

  7. Gupta AK, Lynde CW, Jain HC, Sibbald RG, Elewski BE, Daniel CR 3rd, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol. 1997;136(5):786–9.

    Article  CAS  PubMed  Google Scholar 

  8. Al-Mutairi N, Nour T, Al-Rqobah D. Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, infliximab and Adalimumab. Expert Opin Biol Ther. 2013;13(5):625–9.

    Article  CAS  PubMed  Google Scholar 

  9. Halprin KM. Afflictions of a vestigial appendage. II. Inflammatory processes affecting the nail matrix. (trauma, eczema, psoriasis, lichen planus, alopecia areata). JAMA. 1967;202(11):1045.

    Article  CAS  PubMed  Google Scholar 

  10. Werner B, Fonseca GP, Seidel G. Microscopic nail clipping findings in patients with psoriasis. Am J Dermatopathol. 2015;37(6):429–39.

    Article  PubMed  Google Scholar 

  11. Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–12.

    Article  PubMed  Google Scholar 

  12. Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34(1):123–9.

    PubMed  Google Scholar 

  13. Radtke MA, Beikert FC, Augustin M. Nail psoriasis—a treatment challenge. J Dtsch Dermatol Ges. 2013;11(3):203–19; quiz 20.

    PubMed  Google Scholar 

  14. de Vries AC, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, et al. Interventions for nail psoriasis. Cochrane Database Syst Rev. 2013;31(1):CD007633.

    Google Scholar 

  15. Oram Y, Akkaya AD. Treatment of nail psoriasis: common concepts and new trends. Dermatol Res Pract. 2013;2013:180496.

    PubMed  PubMed Central  Google Scholar 

  16. Langley RG, Saurat JH, Reich K. Nail psoriasis Delphi expert P. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol. 2012;26(3):373–81.

    Article  CAS  PubMed  Google Scholar 

  17. Armstrong AW, Tuong W, Love TJ, Carneiro S, Grynszpan R, Lee SS, et al. Treatments for nail psoriasis: a systematic review by the GRAPPA nail psoriasis work group. J Rheumatol. 2014;41(11):2306–14.

    Article  CAS  PubMed  Google Scholar 

  18. Cannavo SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology. 2003;206(2):153–6.

    Article  CAS  PubMed  Google Scholar 

  19. De Simone C, Maiorino A, Tassone F, D’Agostino M, Caldarola G. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venereol. 2013;27(8):1003–6.

    Article  PubMed  CAS  Google Scholar 

  20. Nakamura RC, Abreu L, Duque-Estrada B, Tamler C, Leverone AP. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. An Bras Dermatol. 2012;87(2):203–11.

    Article  PubMed  Google Scholar 

  21. Tzung TY, Chen CY, Yang CY, Lo PY, Chen YH. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279–80.

    PubMed  Google Scholar 

  22. Rigopoulos D, Gregoriou S, Daniel Iii CR, Belyayeva H, Larios G, Verra P, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338–41.

    Article  CAS  PubMed  Google Scholar 

  23. Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE, et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139(4):655–9.

    Article  CAS  PubMed  Google Scholar 

  24. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis. 2001;68(5):355–8.

    CAS  PubMed  Google Scholar 

  25. Lin YK, See LC, Chang YC, Huang YH, Chen JL, Tsou TC, et al. Treatment of psoriatic nails with indigo naturalis oil extract: a non-controlled pilot study. Dermatology. 2011;223(3):239–43.

    Article  PubMed  Google Scholar 

  26. Farber EM, South DA. Urea ointment in the nonsurgical avulsion of nail dystrophies. Cutis. 1978;22(6):689–92.

    CAS  PubMed  Google Scholar 

  27. Sanchez-Regana M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernandez M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol. 2011;25(5):579–86.

    Article  CAS  PubMed  Google Scholar 

  28. Lindelof B. Psoriasis of the nails treated with grenz rays: a double-blind bilateral trial. Acta Derm Venereol. 1989;69(1):80–2.

    CAS  PubMed  Google Scholar 

  29. Treewittayapoom C, Singvahanont P, Chanprapaph K, Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study. J Am Acad Dermatol. 2012;66(5):807–12.

    Article  PubMed  Google Scholar 

  30. Huang YC, Chou CL, Chiang YY. Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study. Lasers Surg Med. 2013;45(2):102–7.

    Article  PubMed  Google Scholar 

  31. Fernandez-Guarino M, Harto A, Sanchez-Ronco M, Garcia-Morales I, Jaen P. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. J Eur Acad Dermatol Venereol. 2009;23(8):891–5.

    Article  CAS  PubMed  Google Scholar 

  32. Nantel-Battista M, Richer V, Marcil I, Benohanian A. Treatment of nail psoriasis with intralesional triamcinolone acetonide using a needle-free jet injector: a prospective trial. J Cutan Med Surg. 2014;18(1):38–42.

    PubMed  Google Scholar 

  33. Bleeker JJ. Intralesional triamcinolone acetonide using the port-O-jet and needle injections in localized dermatoses. Br J Dermatol. 1974;91(1):97–101.

    Article  CAS  PubMed  Google Scholar 

  34. Gumusel M, Ozdemir M, Mevlitoglu I, Bodur S. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol. 2011;25(9):1080–4.

    Article  CAS  PubMed  Google Scholar 

  35. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011;365(17):1586–96.

    Article  CAS  PubMed  Google Scholar 

  36. Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol. 2009;145(3):269–71.

    Article  CAS  PubMed  Google Scholar 

  37. Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–42.

    Article  CAS  PubMed  Google Scholar 

  38. Feliciani C, Zampetti A, Forleo P, Cerritelli L, Amerio P, Proietto G, et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg. 2004;8(2):122–5.

    Article  PubMed  Google Scholar 

  39. Elewski B. Phase 3 study: 26-week efficacy and safety of adalimumab in patients with nail psoriasis, with and without psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology. 2016;EADV, Vienna, Austria, Poster 2061.

    Google Scholar 

  40. Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147(4):429–36.

    Article  CAS  PubMed  Google Scholar 

  41. Rigopoulos D, Gregoriou S, Lazaridou E, Belyayeva E, Apalla Z, Makris M, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol. 2010;24(5):530–4.

    Article  CAS  PubMed  Google Scholar 

  42. Ortonne JP, Paul C, Berardesca E, Marino V, Gallo G, Brault Y, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168(5):1080–7.

    Article  CAS  PubMed  Google Scholar 

  43. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976–86.

    Article  CAS  PubMed  Google Scholar 

  44. Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58(2):224–31.

    Article  PubMed  Google Scholar 

  45. Reich K, Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS trial. Dermatology. 2010;221(2):172–8.

    Article  CAS  PubMed  Google Scholar 

  46. Saraceno R, Pietroleonardo L, Mazzotta A, Zangrilli A, Bianchi L, Chimenti S. TNF-alpha antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opin Biol Ther. 2013;13(4):469–73.

    Article  CAS  PubMed  Google Scholar 

  47. Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study. J Dermatolog Treat. 2013;24(3):162–8.

    Article  CAS  PubMed  Google Scholar 

  48. Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170(2):398–407.

    Article  CAS  PubMed  Google Scholar 

  49. Igarashi A, Kato T, Kato M, Song M, Nakagawa H. Japanese Ustekinumab study G. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242–52.

    Article  CAS  PubMed  Google Scholar 

  50. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9.

    Article  CAS  PubMed  Google Scholar 

  51. Dennehy EB, Zhang L, Amato D, Goldblum O, Rich P. Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: results from UNCOVER 3. J Drug Dermatol. 2016;15(8):958–61.

    CAS  Google Scholar 

  52. Reich K. TRANSFIGURE: secukinumab efficacy in nail psoriasis: NAPSI % change over 32 weeks. J Eur Acad Dermatol Venereol. 2016;EADV, Vienna, Austria, October, 2016.

    Google Scholar 

  53. Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS, National PF. Treatment of nail psoriasis: best practice recommendations from the medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(1):87–94.

    Article  PubMed  Google Scholar 

  54. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95–102.

    Article  CAS  PubMed  Google Scholar 

  55. Yaemsiri S, Hou N, Slining MM, He K. Growth rate of human fingernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol. 2010;24(4):420–3.

    Article  CAS  PubMed  Google Scholar 

  56. Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28(12):1670–5.

    Article  CAS  PubMed  Google Scholar 

  57. Rigopoulos D, Gregoriou S, Makris M, Ioannides D. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology. 2011;223(4):325–9.

    Article  CAS  PubMed  Google Scholar 

  58. Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24(1):22–7.

    Article  CAS  PubMed  Google Scholar 

  59. Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, et al. Nail assessment in psoriasis and psoriatic arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol. 2014;170(3):591–8.

    Article  CAS  PubMed  Google Scholar 

  60. van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197(4):326–34.

    Article  PubMed  Google Scholar 

  61. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001;2(3):159–65.

    Article  PubMed  Google Scholar 

  62. Sommer B, Overy DP, Kerr RG. Identification and characterization of lipases from Malassezia restricta, a causative agent of dandruff. FEMS Yeast Res. 2015;15(7). https://doi.org/10.1093/femsyr/fov078.

  63. Gomez-Moyano E, Crespo-Erchiga V, Martinez-Pilar L, Godoy Diaz D, Martinez-Garcia S, Lova Navarro M, et al. Do Malassezia species play a role in exacerbation of scalp psoriasis? J Mycol Med. 2014;24(2):87–92.

    Article  CAS  PubMed  Google Scholar 

  64. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004;51(5):785–98.

    Article  PubMed  Google Scholar 

  65. Dobrev H, Zissova L. Effect of ketoconazole 2% shampoo on scalp sebum level in patients with seborrhoeic dermatitis. Acta Derm Venereol. 1997;77(2):132–4.

    CAS  PubMed  Google Scholar 

  66. Faergemann J. Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. A double-blind study. Acta Derm Venereol. 1990;70(2):171–2.

    CAS  PubMed  Google Scholar 

  67. Gupta S. Many faces of Koebner phenomenon in psoriasis. Indian J Dermatol Venereol Leprol. 2002;68(4):222–4.

    PubMed  Google Scholar 

  68. Kim KS, Shin MK, Ahn JJ, Haw CR, Park HK. A comparative study of hair shafts in scalp psoriasis and seborrheic dermatitis using atomic force microscopy. Skin Res Technol. 2013;19(1):e60–4.

    Article  PubMed  Google Scholar 

  69. Shin MK, Kim KS, Ahn JJ, Kim NI, Park HK, Haw CR. Investigation of the hair of patients with scalp psoriasis using atomic force microscopy. Clin Exp Dermatol. 2012;37(2):156–63.

    Article  CAS  PubMed  Google Scholar 

  70. Ruano J, Suarez-Farinas M, Shemer A, Oliva M, Guttman-Yassky E, Krueger JG. Molecular and cellular profiling of scalp psoriasis reveals differences and similarities compared to skin psoriasis. PLoS One. 2016;11(2):e0148450.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Elewski BE. Clinical diagnosis of common scalp disorders. J Investig Dermatol Symp Proc. 2005;10(3):190–3.

    Article  PubMed  Google Scholar 

  72. Woo SM, Choi JW, Yoon HS, Jo SJ, Youn JI. Classification of facial psoriasis based on the distributions of facial lesions. J Am Acad Dermatol. 2008;58(6):959–63.

    Article  PubMed  Google Scholar 

  73. Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138(6):803–7.

    Article  PubMed  Google Scholar 

  74. Amatya B, Wennersten G, Nordlind K. Patients’ perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol. 2008;22(7):822–6.

    Article  CAS  PubMed  Google Scholar 

  75. Runne U, Kroneisen-Wiersma P. Psoriatic alopecia: acute and chronic hair loss in 47 patients with scalp psoriasis. Dermatology. 1992;185(2):82–7.

    Article  CAS  PubMed  Google Scholar 

  76. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74(1):125–30.

    PubMed  Google Scholar 

  77. Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology. 2001;203(2):153–6.

    Article  CAS  PubMed  Google Scholar 

  78. Krell J, Nelson C, Spencer L, Miller S. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol. 2008;58(4):609–16.

    Article  PubMed  Google Scholar 

  79. Kircik L, Fowler J, Weiss J, Meng X, Guana A, Nyirady J. Efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6(4):627–38.

    Article  Google Scholar 

  80. Reygagne P, Mrowietz U, Decroix J, de Waard-van der Spek FB, Acebes LO, Figueiredo A, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat. 2005;16(1):31–6.

    Article  CAS  PubMed  Google Scholar 

  81. Bagel J. Phase 3b study of secukinumab in moderate to severe scalp psoriasis: 12 week results. 2016; Contract No.: EADV, Vienna, 2016 FC04.09.

    Google Scholar 

  82. Andreassi L, Giannetti A, Milani M, Scale IG. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol. 2003;148(1):134–8.

    Article  CAS  PubMed  Google Scholar 

  83. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol. 1994;130(4):483–7.

    Article  CAS  PubMed  Google Scholar 

  84. Mazzotta A, Esposito M, Carboni I, Schipani C, Chimenti S. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat. 2007;18(2):84–7.

    Article  CAS  PubMed  Google Scholar 

  85. Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat. 2006;17(2):90–5.

    Article  CAS  PubMed  Google Scholar 

  86. Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years. Pediatr Dermatol. 2015;32(1):28–35.

    Article  PubMed  Google Scholar 

  87. Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, et al. Topical treatments for scalp psoriasis: summary of a cochrane systematic review. Br J Dermatol. 2017;176(3):604–14.

    Article  CAS  PubMed  Google Scholar 

  88. Feldman SR, Housman TS. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221–4.

    Article  PubMed  Google Scholar 

  89. Alinia H, Moradi Tuchayi S, Smith JA, Richardson IM, Bahrami N, Jaros SC, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–64.

    Article  CAS  PubMed  Google Scholar 

  90. White S, Vender R, Thaci D, Haverkamp C, Naeyaert JM, Foster R, et al. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol. 2006;7(3):177–84.

    Article  PubMed  Google Scholar 

  91. Taneja A, Racette A, Gourgouliatos Z, Taylor CR. Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study. Int J Dermatol. 2004;43(6):462–7.

    Article  PubMed  Google Scholar 

  92. Morison WL, Atkinson DF, Werthman L. Effective treatment of scalp psoriasis using the excimer (308 nm) laser. Photodermatol Photoimmunol Photomed. 2006;22(4):181–3.

    Article  PubMed  Google Scholar 

  93. Taylor CR, Racette AL. A 308-nm excimer laser for the treatment of scalp psoriasis. Lasers Surg Med. 2004;34(2):136–40.

    Article  PubMed  Google Scholar 

  94. Johannesson A, Lindelof B. Additional effect of grenz rays on psoriasis lesions of the scalp treated with topical corticosteroids. Dermatologica. 1987;175(6):290–2.

    Article  CAS  PubMed  Google Scholar 

  95. Lindelof B, Johannesson A. Psoriasis of the scalp treated with Grenz rays or topical corticosteroid combined with Grenz rays. A comparative randomized trial. Br J Dermatol. 1988;119(2):241–4.

    Article  CAS  PubMed  Google Scholar 

  96. Nguyen CM, Leon A, Danesh M, Beroukhim K, Wu JJ, Koo J. Improvement of nail and scalp psoriasis using apremilast in patients with chronic psoriasis: phase 2b and 3, 52-week randomized, placebo-controlled trial results. J Drugs Dermatol. 2016;15(3):272–6.

    CAS  PubMed  Google Scholar 

  97. Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012;67(1):86–92.

    Article  PubMed  Google Scholar 

  98. Thaci D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015;29(2):353–60.

    Article  CAS  PubMed  Google Scholar 

  99. Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2016;13:1–6.

    Google Scholar 

  100. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52(8):2513–8.

    Article  CAS  PubMed  Google Scholar 

  101. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143(2):223–31.

    Article  PubMed  Google Scholar 

  102. Guerra I, Perez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22(4):894–901.

    Article  PubMed  Google Scholar 

  103. Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? J Clin Rheumatol. 2008;14(6):353–6.

    Article  PubMed  Google Scholar 

  104. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60(2):218–24.

    Article  PubMed  Google Scholar 

  105. Puig L, Barco D, Vilarrasa E, Alomar A. Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review. Dermatology. 2010;220(2):154–8.

    Article  PubMed  Google Scholar 

  106. Chung J, Callis Duffin K, Takeshita J, Shin DB, Krueger GG, Robertson AD, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623–32.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271–5.

    Article  PubMed  Google Scholar 

  108. Michaelsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol. 2006;54(4):737–8.

    Article  PubMed  Google Scholar 

  109. Sevrain M, Richard MA, Barnetche T, Rouzaud M, Villani AP, Paul C, et al. Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol. 2014;28(Suppl 5):13–6.

    Article  CAS  PubMed  Google Scholar 

  110. Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, et al. Treatment of pustular psoriasis: from the medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–88.

    Article  CAS  PubMed  Google Scholar 

  111. Khandpur S, Sharma VK. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet a therapy in palmoplantar psoriasis. Clin Exp Dermatol. 2011;36(6):613–6.

    Article  CAS  PubMed  Google Scholar 

  112. Nistico SP, Saraceno R, Chiricozzi A, Giunta A, Di Stefani A, Zerbinati N. UVA-1 laser in the treatment of palmoplantar pustular psoriasis. Photomed Laser Surg. 2013;31(9):434–8.

    Article  PubMed  Google Scholar 

  113. Goldberg DJ, Chwalek J, Hussain M. 308-nm Excimer laser treatment of palmoplantar psoriasis. J Cosmet Laser Ther. 2011;13(2):47–9.

    Article  PubMed  Google Scholar 

  114. Gattu S, Rashid RM, Wu JJ. 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. J Eur Acad Dermatol Venereol. 2009;23(1):36–41.

    Article  CAS  PubMed  Google Scholar 

  115. Nistico SP, Saraceno R, Stefanescu S, Chimenti S. A 308-nm monochromatic excimer light in the treatment of palmoplantar psoriasis. J Eur Acad Dermatol Venereol. 2006;20(5):523–6.

    Article  CAS  PubMed  Google Scholar 

  116. Lozinski A, Barzilai A, Pavlotsky F. Broad-band UVB versus paint PUVA for palmoplantar psoriasis treatment. J Dermatolog Treat. 2016;27(3):221–3.

    Article  CAS  PubMed  Google Scholar 

  117. Sezer E, Erbil AH, Kurumlu Z, Tastan HB, Etikan I. Comparison of the efficacy of local narrowband ultraviolet B (NB-UVB) phototherapy versus psoralen plus ultraviolet a (PUVA) paint for palmoplantar psoriasis. J Dermatol. 2007;34(7):435–40.

    Article  CAS  PubMed  Google Scholar 

  118. Janagond AB, Kanwar AJ, Handa S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study. J Eur Acad Dermatol Venereol. 2013;27(3):e384–9.

    Article  CAS  PubMed  Google Scholar 

  119. Wald JM, Klufas DM, Strober BE. The use of methotrexate, alone or in combination with other therapies, for the treatment of palmoplantar psoriasis. J Drug Dermatol. 2015;14(8):888–92.

    CAS  Google Scholar 

  120. Erkko P, Granlund H, Remitz A, Rosen K, Mobacken H, Lindelof B, et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol. 1998;139(6):997–1004.

    Article  CAS  PubMed  Google Scholar 

  121. Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III efficacy and safety trial evaluating the effects of Apremilast in psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99–105.

    Article  CAS  PubMed  Google Scholar 

  122. Bissonnette R, Poulin Y, Guenther L, Lynde CW, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25(12):1402–8.

    Article  CAS  PubMed  Google Scholar 

  123. Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis. 2003;72(5):396–8.

    PubMed  Google Scholar 

  124. Floristan U, Feltes R, Ramirez P, Alonso ML, De Lucas R. Recalcitrant palmoplantar pustular psoriasis treated with etanercept. Pediatr Dermatol. 2011;28(3):349–50.

    Article  PubMed  Google Scholar 

  125. Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat. 2013;24(3):179–87.

    Article  CAS  PubMed  Google Scholar 

  126. Menter A. UNCOVER-2: impact of ixekizumab on palmoplantar plaque psoriasis. J Am Acad Dermatol. 2016; Poster 3271, Presented at the American Academy of Dermaology, Wahsington DC.

    Google Scholar 

  127. Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80.

    Article  CAS  PubMed  Google Scholar 

  128. Mrowietz U. 2PRECISE: randomized, double-blind, placebo-controlled trial of secukinumab in moderate to severe pustular palmoplantar psoriasis. J Eur Acad Dermatol Venereol. 2016;Poster 2121, European Academy of Dermatology and Venereology, VIenna Austria, October, 2016.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, USA

    Jeffrey J. Crowley MS, MD, FAAD

Authors
  1. Jeffrey J. Crowley MS, MD, FAAD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey J. Crowley MS, MD, FAAD .

Editor information

Editors and Affiliations

  1. Division of Dermatology, David Geffen School of Medicine a UCLA, Los Angeles, California, USA

    Paul S. Yamauchi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Crowley, J.J. (2018). Nail, Scalp, and Palmoplantar Psoriasis. In: Yamauchi, P. (eds) Biologic and Systemic Agents in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-66884-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-66884-0_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-66883-3

  • Online ISBN: 978-3-319-66884-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation